Watchlist Price Alert

Ionis Pharmaceuticals Inc... (IONS)

NASDAQ: IONS · Real-Time Price · USD

33.60

0.82 (2.50%)

At close: May 05, 2025, 3:59 PM

32.81

-2.35%

After-hours: May 05, 2025, 05:53 PM EDT

2.50% (1D)

Bid	32.41
Market Cap	5.35B
Revenue (ttm)	132.2B
Net Income (ttm)	-458.03M
EPS (ttm)	-2.99
PE Ratio (ttm)	-11.24
Forward PE	-10.49
Analyst	Buy

Ask	34.08
Volume	1,618,984
Avg. Volume (20D)	1,749,985
Open	33.22
Previous Close	32.78
Day's Range	32.25 - 33.98
52-Week Range	23.95 - 52.34
Beta	0.29

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 17, 1991

Employees 1,069

Stock Exchange NASDAQ

Ticker Symbol IONS

Website https://www.ionispharma.com

Full Company Profile

Analyst Forecast

According to 18 analyst ratings, the average rating for IONS stock is "Buy." The 12-month stock price forecast is $59, which is an increase of 75.60% from the latest price.

Stock Forecasts

Earnings Surprise

Ionis Pharmaceuticals has released their quartely earnings on Apr 30, 2025:

Revenue of $132M exceeds estimates by $9.49M, with 10.92% YoY growth.

EPS of -0.93 exceeds estimates by 0.10, with -20.78% YoY decline.

Why Price Moved

5 months ago

-7.76%

Shares of pharmaceutical and healthcare stocks are... Unlock content with Pro Subscription

7 months ago

-12.29%

Ionis Pharmaceuticals shares are trading lower after the company priced its $500.3 million public offering of 11.5 million common shares at $43.50 per share.

News

5 days ago · zacks.com

Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View

IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.

6 days ago · seekingalpha.com

Ionis Pharmaceuticals, Inc. (IONS) Q1 2025 Earnings Call Transcript

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q1 2025 Earnings Conference Call April 30, 2025 11:30 AM ET Company Participants Wade Walke - SVP, IR Brett Monia - Founder, CEO & Director Kyle Jenne - EVP ...

6 days ago · benzinga.com

Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis Pharmaceuticals Inc IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.

5 days ago · zacks.com

Ionis Pharmaceuticals (IONS) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare wit...

5 days ago · zacks.com

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $0.98 per share a year ago.

6 days ago · businesswire.com

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were...

1 week ago · zacks.com

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · seekingalpha.com

Ionis: Potentially A Great Time To Buy Ahead Of Q1 Earnings (Upgrade)

Ionis will announce its Q1 earnings on April 30th - in my view, the company is in a strong position and its current valuation of $4.5bn is far too low. The company recently secured approval for olezar...

3 weeks ago · zacks.com

Ionis Pharmaceuticals (IONS) Surges 8.9%: Is This an Indication of Further Gains?

Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...

4 weeks ago · https://thefly.com

Ionis Pharmaceuticals initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Ionis Pharmaceuticals with a Buy rating and $45 price target. Ionis is a commercial-stage biotech company focused on RNA-targeted therapeutics for a range of dise...

Load More News